Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Raiter, A.
Right arrow Articles by Hardy, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raiter, A.
Right arrow Articles by Hardy, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 12, No. 11, 1623-1628, November 2000
© 2000 Japanese Society for Immunology

CD4+ T lymphocytes as a primary cellular target for BAT mAb stimulation

Annat Raiter, Galina Rodionov, Abraham Novogrodsky and Britta Hardy

Felsenstein Medical Research Center, Tel Aviv University, Sackler School of Medicine, Rabin Medical Center, Beilinson Campus, Petah-Tikva 49100, Israel

Correspondence to: B. Hardy

BAT is a monoclonal antibody (mAb) produced against membranes of a human Burkitt lymphoma cell line (Daudi) that was selected for its ability to stimulate lymphocyte proliferation. BAT manifests anti-tumor properties in mice bearing a variety of murine tumors. BAT also induced regression of human tumors inoculated into SCID mice that had been engrafted with human lymphocytes. The anti-tumor activity of BAT was related to its immune stimulatory properties. Previous data indicated that T lymphocytes and NK cells mediate in vivo the anti-tumor activity. In order to define the primary target cell for BAT stimulatory activity, the in vitro stimulatory effect of BAT on purified lymphocyte subpopulations was investigated. Human CD4+, CD8+ T cells and CD56+ NK cells were purified and their in vitro response to BAT was investigated. Results indicate that BAT selectively stimulated CD4+ cells as assessed by proliferation and secretion of IFN-{gamma}. FACS analysis has also revealed a selective increase in BAT antigen on CD4+ T cells that were cultured with BAT antibody. The effector cells that mediate BAT-induced tumor eradication may, however, be distinct from those that serve as the primary cellular target of the antibody. Cytokines such as IFN-{gamma} that are produced by CD4+ cells may be involved in activation of additional cell types that may be involved in tumor destruction.

Keywords: agonistic antibody, BAT receptors, IFN-{gamma}, immune stimulation, T cell activation

Transmitting editor: I. Pecht


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Nair, P. A. Ramaswamy, S. Ghosh, D. C. Joshi, N. Pathak, I. Siddiqui, P. Sharma, S. E. Hasnain, S. C. Mande, and S. Mukhopadhyay
The PPE18 of Mycobacterium tuberculosis Interacts with TLR2 and Activates IL-10 Induction in Macrophage
J. Immunol., November 15, 2009; 183(10): 6269 - 6281.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
B. Hardy, Y. Niv, L. Fadaeev, and A. Raiter
BAT mAb induces lymphopoiesis in nude mice
Int. Immunol., May 1, 2005; 17(5): 615 - 619.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.